摘要
目的观察吡格列酮(PIO)治疗糖尿病患者血管内皮细胞功能的变化及其对胰岛素抵抗(IR)的影响。方法随机选取2型糖尿病伴糖耐量减低(IGT)患者60例为观察组,正常对照组30例。观察组患者用PI0 30 mg/d治疗4个月。治疗前后分别检测反应性充血肱动脉内径增加程度(FMD),含服硝酸甘油后的血管舒张幅度(NID)指标,计算胰岛素敏感指数(ISI)、组织葡萄糖摄取率(GDR)和胰岛素抵抗指数(HOMA-IR)。结果 2型糖尿病糖耐量减低患者治疗前后比较,血糖指标(FBG、HbAlc、HOMA-IR)水平降低,ISI值升高;吡格列酮治疗组与常规治疗组比较,血清脂联素无差异(P>0.05);与正常对照组比较,FMD显著降低,NID无显著性变化;治疗组FMD较治疗前升高,而NID值治疗前后无显著性变化。结论吡格列酮能增加2型糖尿病并发心血管病患者血清脂联素水平,改善IR。
Objective To observe the influence of pioglitazone （PIO） on vascular endothelial cell function and insulin resistance （IR） in the treatmentof diabetic patient. Methods 60 type IIdia- betes patients with impaired glucose tolerance （IGT） were selected as the observation group, and the control group contained 30 healthful patients. Observation group received PIO 30 mg/d for 4 months. Reactive hyperemia of brachial artery diameter （FMD） and the vasodilation amplitude after the oral administration of nitroglycerin （NID） were detected and measured before and after treat- ment. Insulin sensitivity index （ISI）, tissue glucose uptake rate （GDR） and insulin resistance index （HOMA-IR） were calculated meanwhile. Results In observation group, blood sugar index （FBG, HbAlc, homa-ir） level reduced while ISI value raised before and after treatment. After comparison between treatment group and control group, serum adiponectin had no statistical difference （P 〉0. 05）; Compared with control group, FMD significantly reduced and NID had no significant change in observation group; in observation group, FMD increased after treatment than before treatment, while NID value had no significant change before and after treatment. Conclusion Pioglitazone can increase serum adiponectin level and improve IR in treating type 2 diabetes patients with cardiovas- cular disease.
出处
《实用临床医药杂志》
CAS
2012年第23期109-111,共3页
Journal of Clinical Medicine in Practice
基金
中国高校医学期刊临床专项资金(11220234)
关键词
2型糖尿病
心血管并发症
胰岛素抵抗
吡格列酮
type 2 diabetes
cardiovascular complications
Insulin resistance
pioglitazone
